Company profile
Paranovus Entertainment Technology Ltd.
NASDAQ: PAVS · Healthcare · Medical - Pharmaceuticals
#1060 of 1,418 Healthcare companies by revenuebottom-decile growth
EA Score
——FH —DQ 21GM —SS 39
v0.1 · 25/100 weight · pillars only
↑ balance-sheet leverage, return on assets · ↓ filing timeliness, net margin
Methodology →Revenue TTM
$12.5M
Rev growth YoY (TTM)
-81.1%
Net income (FY)
-$7.9M
Employees
29
as of 2026-08-23
Market cap
$4.3M
as of 2026-08-23
Financials — latest annual
SEC EDGAR · USD-normalizedConceptUSDNativeFY
Revenue$71.5k$71.5k2024
Net income-$7.9M-$7.9M2024
Operating income-$6.8M-$6.8M2024
Total assets$35.6M$35.6M2024
Liabilities$6.6M$6.6M2024
Equity$24.3M$24.3M2024
Revenue trend
FY2019 – FY2024 · USD
FY19
FY19
FY20
FY21
FY22
FY23
FY24
FY24
Revenue by segment
Filed disclosures · FY2020
By product
NutraceuticalAndDietarySupplementsMember63%
OnlineStoreMember19%
InternetInformationAndAdvertisingMember13%
AutomobileMember5%
By geography
Not disclosed.
The read
What is Paranovus Entertainment Technology Ltd.’s revenue?
Paranovus Entertainment Technology Ltd. booked $71.5k in FY2024 revenue, contracting 99% year over year — among the slowest-growing Healthcare companies we track, at a -11033.0% net margin.
Peers · Healthcare
Aclarion, Inc.36DSilo Pharma, Inc.39DIMAC Holdings, Inc.——PAVmed Inc.40DExlites Holdings International, Inc.54DeXoZymes, Inc.24DNeighbors
New York →Key facts
CEOXiaoyue Zhang
SectorHealthcare
IndustryMedical - Pharmaceuticals
HeadquartersNew York, NY
ExchangeNASDAQ: PAVS
Employees29
IPO date2019-10-25
Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.